Summary Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.
Malignant melanoma, in humans, belongs to those tumours whose incidence has been rising steadyily over the past few decades (Grin-Jorgensen et al, 1992 ; Glass and Hoover, 1993) . Once disseminated, it is mostly refractory to conventional treatment modalities, and survival rarely exceeds 8 months in patients developing distant metastases (Legha, 1989; Koh, 1991) . However, variability of survival supports the hypothesis of metastatic malignant melanoma as a biologically heterogeneous tumour entity. So far, few preclinical parameters have been established toward prediction of the malignant potential of advanced melanoma.
Protein SI 00 is an acidic calcium-binding protein with a molecular weight of 21 000 Da, consisting of two isomeric subunits called a and 13 (Dannies et al, 1969; Isobe et al, 1981) . Expression of S100 is found in malignant melanoma, and elevated serum levels of S100 have been described in metastatic malignant melanoma (Gaynor et al, 1981; Fagnart et al, 1988) . Previously, increased serum S100 has been identified as a marker of disease progression in metastatic malignant melanoma (Guo et al, 1995) . Therefore, serum S100 might be a useful adjunct in the clinical staging and monitoring of metastatic malignant melanoma. (Atzpodien et al, 1995) ; treatment was continued until further disease progression occurred. Response to therapy was evaluated on an intention-totreat basis and was assessed according to WHO criteria.
Immunoradiometric assay for serum S100 Levels of serum S100 were measured using a monoclonal twosided immunoradiometric sandwich assay (kindly provided by Byk-Sangtec Diagnostics, Dietzenbach, Germany). The monoclonal antibodies detect the 1313 and a13 S100 dimer. All analyses were performed in triplicate strictly according to the procedures recommended by the manufacturers and samples were analysed at a dilution resulting in measured concentrations within the range of the standard curves.
Statistical analysis
The statistical end point in our analysis was overall survival from time of entry into the study. Univariate hazard ratios with 95% confidence intervals were calculated using the Cox proportionalhazards model (Cox, 1972) . Clinical parameters and S100 serum levels were tested as dichotomized prognostic variables. For age, time since tumour progression, time since tumour diagnosis, erythrocyte sedimentation rate (ESR), neutrophil count, haemoglobin, and serum SI00, Kaplan-Meier estimates were performed defining the best cut-off value as the value that best discriminates Figure Serum S100 and cumulative survival in 99 patients malignant melanoma (Kaplan-Meier estimate) . Solid line, lo of S100 (< 3 9tg I-'); dashed line, elevated serum levels of S P-value was determined by the log-rank test. Tick marks rep for whom data were censored between poor and good overall survival; differ( groups in overall survival were tested with the (Kaplan and Meier, 1958) . For lactate dehydrogen C-reactive protein (CRP), the institutional upper were chosen as cut-off (< 240 U 1-1 and < 8 mg 1-The simultaneous prognostic effect of various fact mined in a multivariate analysis using the Cox hazards model (forward selection of variables). T association between two dichotomous variables w( square test, or a two-tailed Fisher's exact test wi values being compared was less than 5.
RESULTS
We assessed the prognostic significance of various clinical factors and of serum S100 in patients with advanced malignant melanoma. The mean follow-up interval was 29 months (range 3-71 months) for the surviving cohort; median survival of all patients entering the study was 10 months.
First, we calculated univariate hazard ratios with the Cox proportional-hazards model (Table 1) . Thus, LDH, ESR, CRP, the presence of liver metastases and the number of metastatic sites showed prognostic significance as to overall survival. Elevated serum levels of S100 (2 3 .tg 1-1) were detected in 22 patients and were associated with an unfavourable outcome; median survival in these patients was 6 months, whereas patients with serum S100 P<0.001 below 3 jtg 1-' (n = 77) achieved a median survival of 13 months 60 72 (P <0.001; Figure 1 ). Elevated serum LDH (.240 U 1-) and increased ESR (. 50 mm h-1) also achieved high prognostic significance upon multivariate analysis (P < 0.001, P < 0.01), with a with metastatic median survival of 5 and 6 months in patients without, and 16 and w serum levels 11 months in patients with, increased LDH and ESR respectively. 100 (a 3 tg 1-1). metastatic sites were not rendered independent by multivariate analysis, serum LDH (P < 0.0001) and the presence of liver metastases (P = 0.04) were found to be significant. The hazard ratio was 0.55 (95% CI 0.43-0.70) for serum LDH and 0.76 (95% CI 0.59-0.98) for liver metastases; thus, both factors were associated with a survival benefit. Elevated serum levels of S 100 were independent of sex, age, the presence of liver metastases and the number of metastatic sites but correlated significantly with increased serum levels of LDH (P < 0.001), and ESR (P < 0.001) ( Table 2) . DISCUSSION Serum 8100 was first described to be elevated in metastatic malignant melanoma by Fagnart et al (1988) . Serum S 100 in the sera of melanoma patients has been thought to be, in part, derived from tumour tissue, as evidenced by the immunohistochemical detection of the S100 protein in malignant melanoma tissue (Gaynor et al, 1981) . More recently, in a preliminary analysis, serum S100 was shown to correlate with the clinical stage of the tumour (Guo et al, 1995) .
In the current study, we found that elevated serum S100 is a prognostic indicator of overall survival in patients with metastatic malignant melanoma. By univariate analysis, the most significant prognostic variables were (a) LDH, (b) S100, (c) erythrocyte sedimentation rate, and (d) liver metastases. Upon multivariate analysis, LDH (P < 0.0001) and the presence of liver metastases (P = 0.04) were the dominant independent prognostic variables. S100 lost its statistical significance upon addition of LDH in the proposed multivariate Cox model, indicating a link between these two prognostic markers.
Serum LDH has been identified as a prognostic parameter in association with tumour burden (Heimdahl et al, 1989; Sirott et al, 1993) . In this study, 41% of patients had elevated serum levels of LDH, but only 29% had confirmed liver metastases. Moreover, serum LDH and the presence of liver metastases were independent prognostic markers upon multivariate analysis. Brain, lung and bone metastases were not associated with a shorter survival; most patients with brain metastases received radiation therapy to the brain, which may have resulted in a long enough survival to allow other factors to be more powerful in predicting the clinical course of disease. In the present study, the number of metastatic sites was not of independent significance. This may be explained in part by the inclusion of serum LDH in this study, which achieved statistical significance as a more accurate marker of tumour burden. Erythrocyte sedimentation rate, which is a known unspecific marker in various human malignancies, did not reach statistical independence.
Several other preclinical parameters have been reported to correlate with disease progression in melanoma, including cytogenetic abnormalities, DNA ploidy and S-phase fraction, the expression of metastasis associated gene products, elevated serum levels of soluble adhesion molecules and the detection of circulating melanoma cells in peripheral blood using reverse transcription-polymerase chain reaction (RT-PCR) for tyrosinase messenger RNA (Trent et al, 1990; Smith et al, 1991; Xerri et al, 1994; Karlsson et al, 1996; Kunter et al, 1996) . These parameters could reflect increase in the total tumour mass, recurrence of the disease or the presence of occult melanoma. Although it remains to be clarified which prognostic markers should be assayed to estimate melanoma progression, our findings suggest SlOO as a good 'stand alone' prognostic marker for overall survival in metastatic malignant melanoma. In conclusion, we currently favour the use of traditional clinical criteria in assessment of the prognosis of metastatic melanoma. Further clinical testing of the above-listed markers is warranted in a multivariate study, also taking into account traditional clinical criteria. As, in the present study, SI00 did not achieve statistical independence upon multivariate analysis, this marker is unlikely to provide any additional information that could be useful for the management and prognosis of metastatic melanoma patients.
